After approval on April 30th, Titan should run a small P2 trial and then file for expedited approval.
Once the delivery system and buprenorphine for addiction is approved, extended trials won't be needed.
If ACAD can file for expedited review for its pos drug, TTNP certainly should be able to.
ACAD's market cap increased by $400M today on the news that they "plan" to file for expedited review.
Come on Sunil, you've got cash now, start the Parkinson's and pain trials!
Get off your fat butt, let's see some advancement of the pipeline.
I would have to check but I thought Sunil said that Braeburn will handle the pain app and will work hard and fast to get it approved. I also read that Braeburn is already talking to docs about pain...
I think something like that will definitely follow the proof of concept approval on April 30th. People are definitely be upset they did not buy more.
Sentiment: Strong Buy